Top entities: Larimar Therapeutics, Pomerantz LLP, Nasdaq-100.

What category does this event fall under?

Regulatory — classified as securities fraud investigation.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Pomerantz LLP investigates claims Larimar Therapeutics · Larimar Therapeutics disclosed anaphylaxis · Larimar Therapeutics issued press release

Is this event still developing?

This is an active story, last updated Jul 14, 2026. Coverage continues to evolve.

Regulatory securities fraud investigation

Pomerantz Investigates Larimar Therapeutics Fraud

Q: When did this event occur?

First reported Jul 01, 2026; last updated Jul 14, 2026.

Q: What is the market impact?

General. The market is negatively impacted by the investigation into Larimar Therapeutics, as its stock price has significantly declined due to safety concerns regarding its drug nomlabofusp.

Analysis based on 14 articles · First reported Jul 01, 2026 · Last updated Jul 14, 2026

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is negatively impacted by the investigation into Larimar Therapeutics, as its stock price has significantly declined due to safety concerns regarding its drug nomlabofusp. This event highlights the risks associated with pharmaceutical development and potential securities fraud, leading to investor uncertainty in the biotechnology sector.

pharmaceuticals legal services

Event Summary

Pomerantz LLP is investigating Larimar Therapeutics, Inc. for alleged securities fraud and unlawful business practices. This investigation stems from two separate disclosures by Larimar Therapeutics regarding its drug nomlabofusp, intended to treat Friedreich s ataxia. On September 29, 2025, Larimar Therapeutics reported anaphylaxis in seven participants, causing its stock to fall 33.66%. On June 29, 2026, Larimar Therapeutics confirmed an ongoing safety signal with anaphylaxis in 10 of 43 patients, leading to another 12.57% stock price drop. These events have prompted Pomerantz LLP to investigate whether Larimar Therapeutics and its officers engaged in misleading investors.

Key Actions

100 Pomerantz LLP investigates claims Larimar Therapeutics

90 Larimar Therapeutics disclosed anaphylaxis

60 Larimar Therapeutics issued press release

Entities Involved

stock

Larimar Therapeutics

Larimar Therapeutics is under investigation by Pomerantz LLP for alleged securities fraud and unlawful business practices related to its drug nomlabofusp, which has shown safety concerns in clinical trials, leading to significant stock price drops.

Importance 100.0 Sentiment -70.0

priv

Pomerantz LLP

Pomerantz LLP is initiating an investigation into Larimar Therapeutics on behalf of its investors, potentially leading to a class action lawsuit.

Importance 80.0 Sentiment 20.0

index

Nasdaq-100

Nasdaq-100 is the stock exchange where Larimar Therapeutics' shares are traded, and its stock price has been negatively impacted by the reported safety concerns and the investigation.

Importance 10.0 Sentiment 0.0

Relationships

Pomerantz LLP related ↔ Nasdaq-100

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard